Egetis Therapeutics AB (OSTO:EGTX) COGS-to-Revenue : 0.39 (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB COGS-to-Revenue?

Egetis Therapeutics AB's Cost of Goods Sold for the three months ended in Sep. 2024 was kr3.70 Mil. Its Revenue for the three months ended in Sep. 2024 was kr9.40 Mil.

Egetis Therapeutics AB's COGS to Revenue for the three months ended in Sep. 2024 was 0.39.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Egetis Therapeutics AB's Gross Margin % for the three months ended in Sep. 2024 was 60.64%.

Egetis Therapeutics AB COGS-to-Revenue Historical Data

The historical data trend for Egetis Therapeutics AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB COGS-to-Revenue Chart

Egetis Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

1.36

4.55

2.52

6.34

3.55

Egetis Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial															0.22	6.08	0.21	0.22	0.39

Egetis Therapeutics AB COGS-to-Revenue Calculation

Egetis Therapeutics AB's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	204.5	/	57.6
	=	3.55

Egetis Therapeutics AB's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.7	/	9.4
	=	0.39

Egetis Therapeutics AB (OSTO:EGTX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Egetis Therapeutics AB's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	3.7 / 9.4
	=	60.64 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Egetis Therapeutics AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Egetis Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

0ABW:UK P0F:Germany

Address

Grev Turegatan 11 C, Stockholm, SWE, 114 46

Website

https://www.egetis.com

Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines